Canadian biopharmaceutical firm Canntab Therapeutics has announced the impending launch of its range of hard pill cannabinoid formulations in Australia with partner Cann Global and its participation in a landmark cannabis research project.
Cann Global has been granted an import permit through its management partnership with Medcan Australia and placed an initial order for Canntab’s products.
Canntab has applied for an export permit with Health Canada and will ship its suite of THC, CBD and THC/CBD hard pill formulations to Cann Global before the end of the year for distribution to doctors, pharmacies and hospitals throughout Australia.
Both companies will also participate in an observational study by Applied Cannabis Research (ACR) described as the largest ever undertaken for medical cannabis.
They will be joined by major Australian clinics and hospitals to complete the Cannabinoid Medicine Observational Study (CMOS), with data collected from 20,000 patients nationwide over five years.
CMOS aims to assess the safety and efficacy of medicinal cannabis products for a range of conditions including fibromyalgia, chronic pain syndromes, PTSD, epilepsy and other mental health and neurological conditions.
ACR will lead the study in conjunction with Australia’s medical community and key industry partners such as Althea Group, Cronos Australia, Cymra Life Sciences, Medcan Australia and Cann Global.
Cann Global managing director Sholom Feldman said: “We are very excited to progress the launch of Canntab’s innovative cannabis-based tablets in Australia which we expect will be highly sought-after by doctors looking to prescribe pharmaceutical grade medicinal cannabis products to their patients.
“It is our understanding from discussions with medical professionals that it is easier for them to prescribe a uniform dosage tablet produced to pharmaceutical grade standards compared to the unreliability of delivery methods used by other products already on the market, giving our product a solid competitive advantage.”
